摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

吡唑并[2,3-a]嘧啶 | 274-71-5

中文名称
吡唑并[2,3-a]嘧啶
中文别名
吡唑[1,5-A]嘧啶;吡唑并[1,5-a]嘧啶
英文名称
pyrazolo[1,5-a]pyrimidine
英文别名
Pyrazolo<1,5-a>pyrimidin;pyrazolo[2,3-a]pyrimidine
吡唑并[2,3-a]嘧啶化学式
CAS
274-71-5
化学式
C6H5N3
mdl
MFCD10699580
分子量
119.126
InChiKey
LDIJKUBTLZTFRG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    105 °C
  • 密度:
    1.29±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302+H312+H332,H315,H319,H335

SDS

SDS:78830da39582c9cefcd13739d0f26f37
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Pyrazolo[1,5-a]pyrimidine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Pyrazolo[1,5-a]pyrimidine
CAS number: 274-71-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5N3
Molecular weight: 119.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

反应信息

  • 作为反应物:
    描述:
    吡唑并[2,3-a]嘧啶 以50%的产率得到
    参考文献:
    名称:
    LYNCH B. M.; KHAN M. A.; SHARMA S. C.; TEO H. C., CAN. J. CHEM. , 1975, 53, NO 1, 119-124
    摘要:
    DOI:
  • 作为产物:
    描述:
    7-Methylthiopyrazolo[1,5-a]pyrimidine 、 三甲基氧鎓四氟硼酸二氯甲烷 为溶剂, 反应 1.0h, 生成 吡唑并[2,3-a]嘧啶
    参考文献:
    名称:
    Cephalosporin compounds
    摘要:
    一种头孢菌素衍生物,其化学式为I:##STR1## 其中X为S、O、CH.sub.2或SO,##STR2## 代表头孢菌素领域已知的C-7酰基之一,R3为氢或甲氧基,R4为氢,可选地取代的烷基、烯丙基、呋喃基或苯甲基,而R5为一种芳香杂环环系,通过碳链相连,其中包含一个季铵化氮原子。
    公开号:
    US05013731A1
点击查看最新优质反应信息

文献信息

  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    申请人:Arora Nidhi
    公开号:US20120015962A1
    公开(公告)日:2012-01-19
    Compounds of the formula I or II: wherein X, m, Ar, R 1 and R 2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    式I或II的化合物: 其中X,m,Ar,R1和R2如本文所定义。所述化合物对于治疗IRAK介导的疾病是有用的。
  • SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
    申请人:OOST Thorsten
    公开号:US20140057916A1
    公开(公告)日:2014-02-27
    This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
    这项发明涉及式1的取代4-吡啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途,包含这些化合物的药物组合物,以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
  • SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS
    申请人:BLUM Andreas
    公开号:US20140135309A1
    公开(公告)日:2014-05-15
    This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R 1 and R 2 are as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    这项发明涉及公式I的新型磺酰胺取代的喹唑啉衍生物,其中Ar、R1和R2如本文所定义,并且它们作为MNK1(MNK1a或MNK1b)和/或MNK2(MNK2a或MNK2b)激酶抑制剂的用途,含有这些化合物的药物组合物,以及将其用作治疗或改善MNK1(MNK1a或MNK1b)和/或MNK2(MNK2a或MNK2b)介导的疾病的药剂的方法。
  • [EN] SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] QUINAZOLINES SUBSTITUÉES PAR SULFOXIMINE POUR COMPOSITIONS PHARMACEUTIQUES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014072244A1
    公开(公告)日:2014-05-15
    This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    这项发明涉及一种新型的配方(I)的磺酰胺取代喹唑啉衍生物,其中Ar、R1和R2如描述和声明中所定义,并且它们作为MNK1(MNK1a或MNK1b)和/或MNK2(MNK2a或MNK2b)激酶抑制剂的用途,含有这些化合物的药物组合物,以及将其用作治疗或改善MNK1(MNK1a或MNK1b)和/或MNK2(MNK2a或MNK2b)介导的疾病的药剂的方法。
  • [EN] PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE<br/>[FR] COMPOSÉS À BASE DE PYRAZOLO[1,5-A] PYRIMIDINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
    申请人:LEXICON PHARMACEUTICALS INC
    公开号:WO2013134228A1
    公开(公告)日:2013-09-12
    Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.
    基于吡唑并[1,5-a]嘧啶的化合物的公式如下:其中R1、R2和R3在此处被定义。还公开了包含这些化合物的组合物以及它们的使用方法,用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和紊乱。
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺